PE20010961A1 - 4-pirimidinil-n-acil-l-fenilalaninas utiles para el tratamiento de enfermedades inflamatorias cronicas - Google Patents
4-pirimidinil-n-acil-l-fenilalaninas utiles para el tratamiento de enfermedades inflamatorias cronicasInfo
- Publication number
- PE20010961A1 PE20010961A1 PE2000001293A PE0012932000A PE20010961A1 PE 20010961 A1 PE20010961 A1 PE 20010961A1 PE 2000001293 A PE2000001293 A PE 2000001293A PE 0012932000 A PE0012932000 A PE 0012932000A PE 20010961 A1 PE20010961 A1 PE 20010961A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- aryl
- pyrimidinyl
- acil
- useful
- Prior art date
Links
- 208000037976 chronic inflammation Diseases 0.000 title 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 title 1
- -1 2-BROMO- 6-METHYLPHENYL Chemical class 0.000 abstract 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- MEWSBKJAUCDJSK-KRWDZBQOSA-N (2s)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxopyrimidin-5-yl)phenyl]propanoic acid Chemical compound O=C1N(C)C(=O)N(C)C(C)=C1C(C=C1)=CC=C1C[C@@H](C(O)=O)NC(=O)C1=C(Cl)C=CC=C1Cl MEWSBKJAUCDJSK-KRWDZBQOSA-N 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical class O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- DUAJIKVIRGATIW-UHFFFAOYSA-N trinitrogen(.) Chemical class [N]=[N+]=[N-] DUAJIKVIRGATIW-UHFFFAOYSA-N 0.000 abstract 1
- 210000005167 vascular cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A 4-PIRIMIDINIL-N-ACIL-L-FENILALANINA DE FORMULA I; DONDE R1 ES Y-1, UN ANILLO HETEROAROMATICO DE 5-6 MIEMBROS; Y-3; R22, R23 SON H, ALQUILO, ALCOXI, ARILALQUILO, ENTRE OTROS; R24 ES H, ALQUILO, ARILO, NITRO, ENTRE OTROS; R25 ES ALQUILO, ALQUENILO, R26-(CH2)e-; R26 ES ARILO, HETEROARILO, AZIDO, NR28R29, ENTRE OTROS; R28 ES H, ALQUILO; R29 ES H, ALQUILO, ALCOXI-CARBONILO, ENTRE OTROS; O R28 Y R29 JUNTO A N FORMAN UN HETEROCICLO DE 4-6 MIEMBROS; Q ES (CH2)fO-, (CH2)fS, (CH2)fN(R27), ENTRE OTROS; R27 ES H, ALQUILO, ARILO, ALCANOILO, ENTRE OTROS; R40 ES H, ALQUILO, ARILO, ENTRE OTROS; e ES 0-4; f ES 0-3; R2 ES H, ALQUILO, ARILALQUILO, ARILO, R3 ES H, ALQUILO, ARILALQUILO, ARILO, ENTRE OTROS; R4 ES H, HALOGENO, ALQUILO, ENTRE OTROS; R5 ES H, ALQUILO, CLORO, CARBOXI; R6 ES H, ALQUILO, P-3, P-4; R32, R33, R34 SON H, ALQUILO; h, g, j SON DE 0-2; h+g ES 1-3; Q' ES O, S, (CH2)j, NR35; R35 ES H, ALQUILO, ALCANOILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N-[(2,6-DICLOROFENIL)CARBONIL]-4-(1,3,6-TRIMETIL-2,4-DIOXO-5-PIRIMIDINIL)-L-FENILALANINA, N-[(2-BROMO-6-METILFENIL)CARBONIL]-4-(1,3,6-TRIMETIL-2,4-DIOXO-5-PIRIMIDINIL)-L-FENILALANINA, ENTRE OTROS. EL COMPUESTO I INHIBE LA UNION DE MOLECULA-1 DE ADHESION A CELULAS VASCULARES VCAM-1, ANTIGENO VLA-4, CELULAS DE EXPRESION DE VLA-4 POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, ENFERMEDADES INFLAMATORIAS INTESTINALES, ASMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16908999P | 1999-12-06 | 1999-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010961A1 true PE20010961A1 (es) | 2001-09-26 |
Family
ID=22614222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001293A PE20010961A1 (es) | 1999-12-06 | 2000-12-05 | 4-pirimidinil-n-acil-l-fenilalaninas utiles para el tratamiento de enfermedades inflamatorias cronicas |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1237878B1 (es) |
| JP (1) | JP3824935B2 (es) |
| KR (1) | KR100522344B1 (es) |
| CN (1) | CN1218943C (es) |
| AR (1) | AR034401A1 (es) |
| AT (1) | ATE357433T1 (es) |
| AU (1) | AU783348B2 (es) |
| BR (1) | BR0016195A (es) |
| CA (1) | CA2392570C (es) |
| CO (1) | CO5080772A1 (es) |
| CY (1) | CY1106626T1 (es) |
| CZ (1) | CZ303435B6 (es) |
| DE (1) | DE60034061T2 (es) |
| DK (1) | DK1237878T3 (es) |
| EG (1) | EG24361A (es) |
| ES (1) | ES2282162T3 (es) |
| HK (1) | HK1054384B (es) |
| HR (1) | HRP20020468B1 (es) |
| HU (1) | HU229105B1 (es) |
| IL (2) | IL149617A0 (es) |
| JO (1) | JO2283B1 (es) |
| MA (1) | MA26850A1 (es) |
| MX (1) | MXPA02005564A (es) |
| MY (1) | MY126972A (es) |
| NO (1) | NO322866B1 (es) |
| NZ (1) | NZ518828A (es) |
| PE (1) | PE20010961A1 (es) |
| PL (1) | PL207160B1 (es) |
| PT (1) | PT1237878E (es) |
| RS (1) | RS50371B (es) |
| RU (1) | RU2266901C2 (es) |
| SI (1) | SI1237878T1 (es) |
| TW (1) | TWI256387B (es) |
| WO (1) | WO2001042225A2 (es) |
| ZA (1) | ZA200203533B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| RU2286340C2 (ru) * | 2000-08-18 | 2006-10-27 | Адзиномото Ко., Инк. | Новые производные фенилаланина |
| AR033765A1 (es) * | 2001-05-22 | 2004-01-07 | Syngenta Participations Ag | Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos. |
| WO2003053926A1 (en) | 2001-12-13 | 2003-07-03 | Ajinomoto Co.,Inc. | Novel phenylalanine derivative |
| EP1700850B1 (en) | 2003-12-22 | 2015-07-15 | Ajinomoto Co., Inc. | Phenylalanine derivative |
| US7618981B2 (en) * | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| WO2006023396A2 (en) * | 2004-08-16 | 2006-03-02 | Merck & Co., Inc. | Vla-4 antagonists |
| JP4784224B2 (ja) | 2004-09-24 | 2011-10-05 | 味の素株式会社 | 糖鎖転移方法および糖鎖転移酵素 |
| US20090137601A1 (en) * | 2005-11-23 | 2009-05-28 | Astrazeneca Ab | L-Phenylalanine Derivatives |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| CN101379028A (zh) * | 2006-02-09 | 2009-03-04 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| CN101472900B (zh) * | 2006-06-19 | 2011-07-27 | 东丽株式会社 | 多发性硬化症的治疗或预防药 |
| UY31344A1 (es) * | 2007-09-17 | 2009-04-30 | Metansulfonamidas n-(3-ter-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-2-metoxi-aril) sustituidas, solvatos, hidratos, formas cristalinas y sus sales farmacéuticamente aceptables,proceso de preparación,composiciones y aplicaciones. | |
| DK2203430T3 (da) | 2007-09-17 | 2011-09-26 | Abbott Lab | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) |
| CN104628654A (zh) | 2007-09-17 | 2015-05-20 | 艾伯维巴哈马有限公司 | 抗感染嘧啶及其用途 |
| KR101701395B1 (ko) * | 2008-12-22 | 2017-02-01 | 아이씨엘-아이피 아메리카 아이엔씨. | 비스포스페이트를 정제하기 위한 수용성 용매 기반 정제 방법 |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| SG187102A1 (en) | 2010-07-16 | 2013-02-28 | Abbvie Inc | Process for preparing antiviral compounds |
| UA113498C2 (xx) | 2010-07-16 | 2017-02-10 | Фосфінові ліганди для каталітичних реакцій | |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| JP6159740B2 (ja) * | 2012-01-27 | 2017-07-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｖｌａ−４を発現する細胞への標的化送達のためのインテグリンアンタゴニスト結合体 |
| US9447035B2 (en) * | 2012-01-27 | 2016-09-20 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| PT3064491T (pt) * | 2013-10-29 | 2020-02-20 | Ea Pharma Co Ltd | Derivado de sulfonamida e sua utilização medicinal |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| ES3003232T3 (en) | 2018-10-30 | 2025-03-10 | Gilead Sciences Inc | Compounds for inhibition of alpha4beta7 integrin |
| CN112969687B (zh) | 2018-10-30 | 2024-08-23 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
| EP3873900B1 (en) | 2018-10-30 | 2025-01-08 | Gilead Sciences, Inc. | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| CA3148613A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH516578A (de) * | 1967-11-02 | 1971-12-15 | Bayer Ag | Verfahren zur Herstellung von heterocyclische Acylaminogruppen enthaltenden Arylsulfonylharnstoffen mit blutdrucksenkender Wirkung |
| AU726585B2 (en) * | 1997-05-29 | 2000-11-09 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
| EP1001764A4 (en) * | 1997-05-29 | 2005-08-24 | Merck & Co Inc | HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION |
| PT1005445E (pt) * | 1997-08-22 | 2004-09-30 | Hoffmann La Roche | Derivados de n-alcanoilfenilalanina |
| PT1005446E (pt) * | 1997-08-22 | 2004-06-30 | Hoffmann La Roche | Derivados de n-aroilfenilalanina |
| HK1045495A1 (zh) * | 1999-01-22 | 2002-11-29 | 依兰制药公司 | 抑制vla-4介导的白细胞粘着的多环化合物 |
-
2000
- 2000-11-28 DK DK00989906T patent/DK1237878T3/da active
- 2000-11-28 IL IL14961700A patent/IL149617A0/xx active IP Right Grant
- 2000-11-28 MX MXPA02005564A patent/MXPA02005564A/es active IP Right Grant
- 2000-11-28 JP JP2001543526A patent/JP3824935B2/ja not_active Expired - Fee Related
- 2000-11-28 BR BR0016195-0A patent/BR0016195A/pt active Search and Examination
- 2000-11-28 DE DE60034061T patent/DE60034061T2/de not_active Expired - Lifetime
- 2000-11-28 PL PL357601A patent/PL207160B1/pl unknown
- 2000-11-28 CA CA2392570A patent/CA2392570C/en not_active Expired - Fee Related
- 2000-11-28 AU AU26696/01A patent/AU783348B2/en not_active Ceased
- 2000-11-28 EP EP00989906A patent/EP1237878B1/en not_active Expired - Lifetime
- 2000-11-28 ES ES00989906T patent/ES2282162T3/es not_active Expired - Lifetime
- 2000-11-28 HK HK03106628.4A patent/HK1054384B/zh not_active IP Right Cessation
- 2000-11-28 AT AT00989906T patent/ATE357433T1/de active
- 2000-11-28 RU RU2002117422/04A patent/RU2266901C2/ru not_active IP Right Cessation
- 2000-11-28 HR HR20020468A patent/HRP20020468B1/xx not_active IP Right Cessation
- 2000-11-28 CZ CZ20022351A patent/CZ303435B6/cs not_active IP Right Cessation
- 2000-11-28 WO PCT/EP2000/011884 patent/WO2001042225A2/en not_active Ceased
- 2000-11-28 KR KR10-2002-7007175A patent/KR100522344B1/ko not_active Expired - Fee Related
- 2000-11-28 PT PT00989906T patent/PT1237878E/pt unknown
- 2000-11-28 CN CNB008167958A patent/CN1218943C/zh not_active Expired - Fee Related
- 2000-11-28 NZ NZ518828A patent/NZ518828A/en not_active IP Right Cessation
- 2000-11-28 SI SI200030948T patent/SI1237878T1/sl unknown
- 2000-11-28 RS YUP-404/02A patent/RS50371B/sr unknown
- 2000-11-28 HU HU0204081A patent/HU229105B1/hu not_active IP Right Cessation
- 2000-11-29 JO JO2000190A patent/JO2283B1/en active
- 2000-12-03 EG EG20001502A patent/EG24361A/xx active
- 2000-12-04 MY MYPI20005690A patent/MY126972A/en unknown
- 2000-12-04 AR ARP000106415A patent/AR034401A1/es not_active Application Discontinuation
- 2000-12-05 TW TW089125890A patent/TWI256387B/zh not_active IP Right Cessation
- 2000-12-05 PE PE2000001293A patent/PE20010961A1/es not_active Application Discontinuation
- 2000-12-05 CO CO00092691A patent/CO5080772A1/es unknown
-
2002
- 2002-05-03 ZA ZA200203533A patent/ZA200203533B/en unknown
- 2002-05-13 IL IL149617A patent/IL149617A/en not_active IP Right Cessation
- 2002-06-04 NO NO20022633A patent/NO322866B1/no not_active IP Right Cessation
- 2002-06-05 MA MA26673A patent/MA26850A1/fr unknown
-
2007
- 2007-05-29 CY CY20071100715T patent/CY1106626T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010961A1 (es) | 4-pirimidinil-n-acil-l-fenilalaninas utiles para el tratamiento de enfermedades inflamatorias cronicas | |
| PE20010960A1 (es) | 4-piridinil-n-acil-l-fenilalaninas inhibidores de la interaccion entre integrina vla-4 y vcam-1 | |
| PE107399A1 (es) | Derivados de n-alcanoilfenilalanina | |
| RU2333205C2 (ru) | Производные бензотиадиазепина, способ их получения и их применение, фармацевтическая композиция, обладающая ингибирующей активностью в отношении переноса желчных кислот в подвздошной кишке | |
| RU94024563A (ru) | Арилзамещенные гетероциклы, способ их получения, фармацевтическая композиция на их основе | |
| BRPI0417605B8 (pt) | n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende. | |
| ATE56205T1 (de) | Heterocyclische amide. | |
| ATE98245T1 (de) | Azaindene. | |
| EP1502603A4 (en) | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM | |
| NO931529D0 (no) | Cykliske fruktopyranosesulfitter og -sulfater med antikonvulsiv effekt | |
| GR3015558T3 (en) | Chemically modified protein and production thereof. | |
| KR930700514A (ko) | 항미생물성 퀴놀로닐 락탐 | |
| ATE162715T1 (de) | Verwendung von schwefel enthaltenden carbonsäuren zur bekämpfung von pathophysiologisch bedingten erregungsstörungen | |
| KR890003385A (ko) | 항 증식제로서 유용한 5-아미노 또는 치환된 아미도 1,2,3-트리아졸 | |
| NO891501D0 (no) | Hetera-alifatiske karboksamider. | |
| ATE66212T1 (de) | N-(w-substituierte alkyl)-n'-((imidazol-4yl)alkyl>guanidine. | |
| ATE20234T1 (de) | Aroylaminosaeuren. | |
| KR920006337A (ko) | 헤테로 아릴 메틸 벤젠 | |
| KR870006038A (ko) | N-(피롤-1-일)피리딘아민 및 그의 제조방법 | |
| DE69836546D1 (de) | Menschliches, durch kalzium aktivierbares kaliumkanalpolypeptid aus leukozyten | |
| IT1251500B (it) | Stabilizzazione dopo trattamento di emulsioni fototermografiche | |
| KR860000271A (ko) | 치환된 페닐술포닐우레아의 제조방법 | |
| ATE81016T1 (de) | Anwendung heterozyklischer dervate zur herstellung von arzneimitteln. | |
| ATE73132T1 (de) | Leukotrien-antagonisten. | |
| BR0202157A (pt) | Peptìdeo obtido de veneno escorpião para uso como agente hipotensivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |